NO995568L - Paratyroidhormon peptidanaloger - Google Patents

Paratyroidhormon peptidanaloger

Info

Publication number
NO995568L
NO995568L NO995568A NO995568A NO995568L NO 995568 L NO995568 L NO 995568L NO 995568 A NO995568 A NO 995568A NO 995568 A NO995568 A NO 995568A NO 995568 L NO995568 L NO 995568L
Authority
NO
Norway
Prior art keywords
parathyroid hormone
peptide analogs
hormone peptide
analogs
parathyroid
Prior art date
Application number
NO995568A
Other languages
English (en)
Norwegian (no)
Other versions
NO995568D0 (no
Inventor
Stephen M Condon
Isabelle Morize
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of NO995568D0 publication Critical patent/NO995568D0/no
Publication of NO995568L publication Critical patent/NO995568L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO995568A 1997-05-14 1999-11-12 Paratyroidhormon peptidanaloger NO995568L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4647297P 1997-05-14 1997-05-14
PCT/US1998/009843 WO1998051324A1 (en) 1997-05-14 1998-05-13 Peptide parathyroid hormone analogs

Publications (2)

Publication Number Publication Date
NO995568D0 NO995568D0 (no) 1999-11-12
NO995568L true NO995568L (no) 1999-12-29

Family

ID=21943653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995568A NO995568L (no) 1997-05-14 1999-11-12 Paratyroidhormon peptidanaloger

Country Status (20)

Country Link
US (2) US6472505B1 (zh)
EP (1) EP0986395A4 (zh)
JP (1) JP2001517957A (zh)
KR (1) KR100351213B1 (zh)
CN (1) CN1261281A (zh)
AP (1) AP9901686A0 (zh)
AU (1) AU746461B2 (zh)
BG (1) BG103957A (zh)
BR (1) BR9808786A (zh)
CA (1) CA2290443A1 (zh)
EA (1) EA002819B1 (zh)
HU (1) HUP0003349A3 (zh)
IL (1) IL132901A0 (zh)
NO (1) NO995568L (zh)
OA (1) OA11216A (zh)
PL (1) PL336803A1 (zh)
SK (1) SK151599A3 (zh)
UA (1) UA62967C2 (zh)
WO (1) WO1998051324A1 (zh)
ZA (1) ZA984077B (zh)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052933A1 (en) 1998-04-15 1999-10-21 Aventis Pharmaceuticals Products Inc. Process for the preparation of resin-bound cyclic peptides
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US20040023882A1 (en) * 2002-05-16 2004-02-05 Peri Krishna G. PTH derivatives resistant to skin proteases
WO2004073587A2 (en) * 2003-02-19 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1)
JP2007533596A (ja) * 2003-07-15 2007-11-22 ナショナル・リサーチ・カウンシル・オブ・カナダ 異常増殖性皮膚細胞を特徴とする状態の処置のためのヒト副甲状腺ホルモンの環状アナログ
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
JP5086254B2 (ja) 2005-07-07 2012-11-28 フルクルム エスピー リミテッド Ｓｐ１ポリペプチド、変性ｓｐ１ポリペプチドおよびそれらの使用
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
SI2084183T1 (sl) * 2006-10-13 2010-09-30 Lilly Co Eli Pegilirani pth kot modulatorji pth receptorja in njihove uporabe
US8691760B2 (en) 2009-02-02 2014-04-08 Ramot At Tel-Aviv University Peptides, pharmaceutical compositions comprising same and uses thereof
JP2012522762A (ja) 2009-04-01 2012-09-27 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター ケラチノサイトの増殖および分化を調節する方法
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2011138785A2 (en) 2010-05-05 2011-11-10 Rappaport Family Institute For Research In The Medical Sciences Use of ccl1 in therapy
BR112012028949B1 (pt) * 2010-05-13 2020-11-17 Chugai Seiyaku Kabushiki Kaisha polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN103534867B (zh) * 2011-06-17 2017-04-12 流体公司 含有磺酸根离子的离子液体
KR101912982B1 (ko) 2012-03-06 2018-10-29 셀렉트 바이오테라퓨틱스 리미티드 세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof
US20160340659A1 (en) 2014-01-30 2016-11-24 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same
WO2015145449A2 (en) 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
WO2016128971A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of bone fractures and defects
CA2977607A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
US11820833B2 (en) 2016-06-05 2023-11-21 Tel Hashomer Medical Research Infrastructure And Services Ltd. Peptides that inhibit binding of EPCR to its ligand to treat inflammation
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
CA3026989C (en) 2016-12-01 2023-07-11 Ramot At Tel-Aviv University Ltd. Combined treatment for nerve injuries
US20200121581A1 (en) 2017-04-07 2020-04-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hair care compositions
US20200172604A1 (en) 2017-05-23 2020-06-04 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
WO2019016819A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NANOPARTICLE COMPOSITIONS
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
US20200390800A1 (en) 2017-11-29 2020-12-17 Ramot At Tel-Aviv University Ltd. Methods of preventing or treating neurogenic shock
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
AU2020311636A1 (en) 2019-07-11 2022-03-03 Kahr Medical Ltd. Heterodimers and methods of use thereof
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN115335532A (zh) 2020-02-09 2022-11-11 Nlc制药有限公司 Sars-cov-2快速检测测试
EP4114473A1 (en) 2020-03-05 2023-01-11 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
EP4121441A1 (en) 2020-03-16 2023-01-25 Yeda Research and Development Co. Ltd Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
EP4217370A2 (en) 2020-09-23 2023-08-02 Yeda Research and Development Co. Ltd Methods and compositions for treating coronaviral infections
WO2022074656A1 (en) 2020-10-07 2022-04-14 Protalix Ltd. Long-acting dnase
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
JP2024506955A (ja) 2021-02-18 2024-02-15 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ワクチンを作製する方法
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
WO2023031934A1 (en) 2021-09-02 2023-03-09 Yeda Research And Development Co. Ltd. Agents that target the glycine arginine-rich domain of nucleolin and uses thereof
WO2024038462A1 (en) 2022-08-17 2024-02-22 Yeda Research And Development Co. Ltd. Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4427827A (en) 1982-10-20 1984-01-24 Usv Pharmaceutical Corporation Synthesis of hormone fragments
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
CA2087087C (en) 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
CA2098639A1 (en) 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE19508672A1 (de) * 1995-03-10 1996-09-12 Boehringer Mannheim Gmbh Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5717062A (en) * 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
CA2178392A1 (en) 1995-06-07 1996-12-08 Robert W. Horst Fail-fast, fail-functional, fault-tolerant multiprocessor system
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
WO1998005683A1 (en) * 1996-08-02 1998-02-12 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis

Also Published As

Publication number Publication date
EA002819B1 (ru) 2002-10-31
EA199901025A1 (ru) 2000-06-26
OA11216A (en) 2003-07-10
HUP0003349A2 (hu) 2001-01-29
KR20010012568A (ko) 2001-02-15
BR9808786A (pt) 2000-07-11
US6472505B1 (en) 2002-10-29
CN1261281A (zh) 2000-07-26
ZA984077B (en) 1998-11-24
KR100351213B1 (ko) 2002-09-05
AU746461B2 (en) 2002-05-02
US20020132973A1 (en) 2002-09-19
AP9901686A0 (en) 1999-12-31
NO995568D0 (no) 1999-11-12
WO1998051324A1 (en) 1998-11-19
BG103957A (bg) 2000-04-28
EP0986395A1 (en) 2000-03-22
JP2001517957A (ja) 2001-10-09
EP0986395A4 (en) 2004-12-01
HUP0003349A3 (en) 2001-12-28
PL336803A1 (en) 2000-07-17
CA2290443A1 (en) 1998-11-19
SK151599A3 (en) 2000-09-12
AU7386798A (en) 1998-12-08
IL132901A0 (en) 2001-03-19
UA62967C2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
NO995568D0 (no) Paratyroidhormon peptidanaloger
ATE245165T1 (de) Kristallines parathyroidhormon
IL130794A0 (en) Analogs of parathyroid hormone
NO2010013I1 (no) Rekombinant FSH-CTP
NO974269D0 (no) Lipofile peptidhormonderivater
DE4393381T1 (de) Peptide
EE03832B1 (et) Heptapeptiidanaloogid
DE69831486D1 (de) Antiproliferative zubereitungen
DE69722620D1 (de) Nicht-waessrige protische peptidzubereitungen
NO982097D0 (no) Peptider
NO982098D0 (no) Peptider
DE69941708D1 (de) Pacap-peptidanaloga
DE69911579D1 (de) Antimikrobielle peptide
NO985680L (no) Peptidderivater
LV10962A (lv) Jauni peptidi
NO983849D0 (no) Peptidderivater
EE04001B1 (et) Peptiidne farmatseutiline kompositsioon
NO995299L (no) Kalsitonin reseptorbindende peptider
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
DK1230369T3 (da) Polypeptidhormon phosphatonin
ATE235511T1 (de) Vielfältig verzweigte peptidkonstruktionen
ATE277076T1 (de) Antineoplastische peptide
NO20012283D0 (no) Koblede peptider
ZA9861B (en) Analogs of parathyroid hormone
DK1017798T3 (da) Lunasinpeptider

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application